Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspira Women's Health Inc. (AWHL) SEC filings page on Stock Titan brings together the company’s official regulatory documents, offering a detailed view of its operations, capital structure, and risk profile. Aspira is a smaller reporting company in the diagnostics and research segment of healthcare, focused on noninvasive, AI-powered tests for gynecologic diseases such as ovarian cancer and endometriosis.
Through registration statements on Form S-1 and S-1/A, Aspira outlines its business model, including its OvaSuite℠ portfolio of ovarian cancer risk assessment tests (OvaWatch® and Ova1Plus®), its CLIA laboratory operations, and its development pipeline for the ENDOinform™ endometriosis test. These filings also describe the company’s plans to commercialize its technology, its use of multi-omics biomarkers and AI algorithms, and its status as a non-accelerated filer and smaller reporting company.
Investors can review Form 8-K current reports for material events such as private placements of convertible notes and warrants, equity purchase agreements, laboratory services agreements, listing changes from OTCQB to OTCQX, and updates on government-funded programs. Filings detailing purchase agreements with institutional investors and equity line arrangements provide insight into how Aspira raises capital to support its commercial and R&D activities.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that help explain complex sections of Aspira’s filings. Users can quickly understand key elements of annual and quarterly reports when available, including product revenue composition, operating expense trends, and liquidity discussions, as disclosed in the company’s financial statements. Form 4 insider transaction reports, when filed, can be accessed to see how directors and officers transact in AWHL shares.
Use this SEC filings hub to navigate Aspira’s S-1 and S-1/A registration statements, 8-K and 8-K/A current reports, and other disclosures. The AI-generated overviews are designed to highlight important terms, financing structures, and business descriptions so that readers can more efficiently interpret Aspira Women’s Health Inc.’s regulatory record.
Aspira Women’s Health filed Amendment No. 1 to a Form S-1 to register the resale of up to 29,226,527 shares of common stock by selling stockholders. The registered shares comprise: 5,915,850 issued on conversion of senior secured convertible notes, 11,848,177 issuable upon exercise of Amended and Restated March 2025 Warrants, 6,550,000 issued under the September 2025 Purchase Agreement, and 4,912,500 issuable upon exercise of September 2025 Warrants.
The company is not selling any securities in this prospectus and will not receive proceeds from stockholder resales. If the Amended and Restated March 2025 Warrants or September 2025 Warrants are exercised for cash, Aspira estimates it would receive $7,831,237. Sales may occur from time to time using methods described under “Plan of Distribution.” Aspira’s common stock trades on the OTCQB as AWHL; the closing price was $0.52 on September 29, 2025. Shares outstanding were 42,655,918 as of September 29, 2025.
Aspira Women’s Health Inc. reported that on October 14, 2025 it upgraded its trading venue to OTCQX from the OTCQB Venture Market. The company now trades on OTCQX under the symbol AWHL.
Aspira Womens Health Inc. (AWHL) filed a registration statement to register up to 29,226,527 resale shares of its common stock held by selling stockholders. The resale pool comprises shares issued on conversion of convertible notes, shares underlying amended March 2025 warrants, shares issued under a September 2025 purchase agreement, and shares underlying September 2025 warrants. After giving effect to the offering the company expects 59,416,595 shares outstanding based on 42,655,918 shares outstanding as of September 29, 2025. The company will not receive proceeds from the resale by selling stockholders; however, it would receive the nominal cash exercise price if the listed warrants are exercised, estimated at $7,831,237. The prospectus highlights numerous risk factors including limited daily trading volume and concerns about the companys ability to continue as a going concern.
Aspira Women’s Health Inc. entered into an amendment to its March 2025 securities purchase agreement covering a prior $1,370,000 private placement of Senior Secured Convertible Promissory Notes, all of which have now converted into units of common stock and warrants. The amendment requires Aspira to file a Form S-1 registration statement by September 30, 2025 to register the common shares and the shares underlying the warrants issued in that financing.
The amendment also grants the participating purchasers, as a group, the right to appoint up to three directors to the board until the earlier of specified time and listing milestones or until their aggregate warrant holdings fall below fifty percent. In connection with this change, Aspira issued Amended and Restated Series A Common Stock Warrants, which now have a fixed exercise price of $0.35 per share, must be exercised for cash, have their term extended to six years from issuance, and begin to be exercisable six months after the issuance date.
Aspira Women's Health Inc. insider purchase and holdings update. Director Jack W. Schuler, as sole trustee of the Jack W. Schuler Living Trust, reported purchases and existing holdings in AWHL securities. On 09/17/2025 he purchased 1,111,111 shares of common stock at $0.45 per share and now beneficially owns 3,823,829 shares indirectly through the Living Trust. The filing also reports warrants totaling 2,661,422 underlying common shares across multiple strike prices and expirations, including an acquisition of 833,333 warrants exercisable at $0.75 (expiring 09/17/2030). A small disposition of 6,536 common shares and a prior disposal of 6,536 warrants at $2.25 are noted. The report is signed by Jack W. Schuler on 09/18/2025.
Jeffrey K. Cohen, a director of Aspira Women's Health Inc. (AWHL), reported insider purchases on 09/17/2025. He acquired 55,556 shares of common stock at $0.45 per share and received 41,667 warrants exercisable immediately and expiring 09/17/2030, each warrant underlying one share. Following the reported transactions, the filing shows 375,697 shares beneficially owned indirectly (via HealthView Asset Management) and 60,913 shares indirectly by spouse.
Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.
John D. Fraser, a director of Aspira Women's Health Inc. (AWHL), reported purchases on 09/17/2025. He acquired 16,389 shares of common stock at $0.45 per share and purchased 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030) covering 12,292 shares. After these transactions he reports beneficial ownership of 566,393 shares directly and 291,554 indirectly through Seamark Capital; 981,549 derivative securities are shown as owned.
Aspira Women's Health Inc. filed a Form D reporting a Regulation D offering under Rule 506(b). The company stated a $2,950,000 total offering size and reports $2,950,000 sold with $0 remaining, indicating the offering has been fully sold. The first sale date is listed as 2025-09-16. The securities offered include equity, options/warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. The filing lists 19 investors to date, indicates the offering will not last more than one year, and shows $0 in sales commissions and finders' fees. The company disclosed $0 of proceeds paid to named executive officers, directors or promoters. The Form D was signed by Michael Buhle, Chief Executive Officer, on 2025-09-18.
Aspira Women’s Health Inc. entered into securities purchase agreements for a private placement of 6,550,000 shares of common stock and accompanying warrants to purchase up to 4,912,500 additional shares. The securities were sold at $0.45 per share of common stock plus accompanying warrant.
The warrants are exercisable immediately at $0.75 per share and have a five-year term from issuance. The transaction closed on September 17, 2025, generating approximately $2.95 million in gross proceeds, which the company plans to use for working capital and general corporate purposes.